NEW YORK (GenomeWeb News) - Thomson Reuters said today that the National Cancer Institute will use the company’s BiomarkerCenter database to support its research on potential cancer therapeutics.
 
Thomson Reuters said that NCI’s Developmental Therapeutics program and its associated Biomarker Program will use BiomarkerCenter, a database of information on biomarkers that alerts uses to status changes of biomarkers of interest. The company launched the database in June.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.